Teresa Brophy Bair Sells 11,208 Shares of Kura Oncology (NASDAQ:KURA) Stock

Kura Oncology, Inc. (NASDAQ:KURA) insider Teresa Brophy Bair sold 11,208 shares of the stock in a transaction that occurred on Tuesday, January 27th. The shares were sold at an average price of $8.46, for a total value of $94,819.68. Following the completion of the sale, the insider directly owned 226,931 shares of the company’s stock, valued at $1,919,836.26. This represents a 4.71% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Teresa Brophy Bair also recently made the following trade(s):

• On Friday, November 14th, Teresa Brophy Bair sold 8,804 shares of Kura Oncology stock. The stock was sold at an average price of $11.18, for a total transaction of $98,428.72.

Kura Oncology Stock Performance

Kura Oncology stock traded down $0.10 during mid-day trading on Tuesday, reaching $8.47. The company had a trading volume of 1,149,028 shares, compared to its average volume of 1,287,347. The company has a quick ratio of 5.12, a current ratio of 5.12 and a debt-to-equity ratio of 0.02. The firm has a market cap of $737.06 million, a price-to-earnings ratio of -3.42 and a beta of 0.25. The company has a 50 day moving average of $10.33 and a 200-day moving average of $9.05. Kura Oncology, Inc. has a 52 week low of $5.41 and a 52 week high of $12.49.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings data on Tuesday, November 4th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.28). Kura Oncology had a negative return on equity of 65.42% and a negative net margin of 208.48%.The company had revenue of $20.75 million for the quarter, compared to the consensus estimate of $17.48 million. On average, sell-side analysts expect that Kura Oncology, Inc. will post -2.44 EPS for the current fiscal year.

Institutional Investors Weigh In On Kura Oncology

Institutional investors and hedge funds have recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Kura Oncology by 41.4% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 46,363 shares of the company’s stock worth $482,000 after purchasing an additional 13,579 shares during the last quarter. Merit Financial Group LLC lifted its holdings in Kura Oncology by 124.0% during the 4th quarter. Merit Financial Group LLC now owns 22,499 shares of the company’s stock valued at $234,000 after purchasing an additional 12,454 shares during the last quarter. Xcel Wealth Management LLC boosted its position in Kura Oncology by 16.2% in the fourth quarter. Xcel Wealth Management LLC now owns 118,846 shares of the company’s stock valued at $1,235,000 after buying an additional 16,525 shares in the last quarter. CWM LLC grew its stake in Kura Oncology by 32.3% during the fourth quarter. CWM LLC now owns 156,544 shares of the company’s stock worth $1,626,000 after buying an additional 38,181 shares during the last quarter. Finally, Flower City Capital grew its stake in Kura Oncology by 20.0% during the fourth quarter. Flower City Capital now owns 12,000 shares of the company’s stock worth $125,000 after buying an additional 2,000 shares during the last quarter.

Analysts Set New Price Targets

Several analysts have recently weighed in on KURA shares. Wedbush reissued an “outperform” rating and set a $38.00 price objective (up previously from $36.00) on shares of Kura Oncology in a report on Friday, November 14th. Citigroup reaffirmed a “market outperform” rating on shares of Kura Oncology in a research report on Friday, December 5th. HC Wainwright reissued a “buy” rating and issued a $40.00 price target on shares of Kura Oncology in a report on Tuesday, January 13th. UBS Group increased their price objective on shares of Kura Oncology from $14.00 to $16.00 and gave the company a “buy” rating in a research note on Friday, November 14th. Finally, Zacks Research lowered shares of Kura Oncology from a “hold” rating to a “strong sell” rating in a research report on Tuesday, January 20th. Nine analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, Kura Oncology has a consensus rating of “Moderate Buy” and an average target price of $28.00.

Kura Oncology Company Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.